Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Lung Cancer, Non-Small Cell
DRUG: pazopanib|DRUG: paclitaxel
Phase I: safety and tolerability (Serious adverse events, adverse events, dose-limiting toxicities, clinical laboratory data, vital signs, ECG, ECOG performance status), at least one cycle of treatment (3 weeks)
Phase I: paclitaxel and pazopanib pharmacokinetics, Cycle 1 and Cycle 2 PK sampling|Phase I: clinical activity, at least 6 weeks
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.